Cord Blood Stem Cell Transplantation: Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.Fetal Blood: Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Peripheral Blood Stem Cell Transplantation: Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.Monocrotophos: An organophosphate insecticide that inhibits monoamine oxidase and acetylcholinesterase. It has been shown to be genotoxic.Stem Cells: Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Stem Cell Transplantation: The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.Transplantation, Homologous: Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.Penile Implantation: Surgical insertion of cylindric hydraulic devices for the treatment of organic ERECTILE DYSFUNCTION.Umbilical Cord: The flexible rope-like structure that connects a developing FETUS to the PLACENTA in mammals. The cord contains blood vessels which carry oxygen and nutrients from the mother to the fetus and waste products away from the fetus.Philosophy, NursingMale Urogenital Diseases: Pathological processes of the male URINARY TRACT and the reproductive system (GENITALIA, MALE).Blood Banks: Centers for collecting, characterizing and storing human blood.Personnel Staffing and Scheduling Information Systems: Computer-based systems for use in personnel management in a facility, e.g., distribution of caregivers with relation to patient needs.Hematopoietic Stem Cells: Progenitor cells from which all blood cells derive.Histone Deacetylases: Deacetylases that remove N-acetyl groups from amino side chains of the amino acids of HISTONES. The enzyme family can be divided into at least three structurally-defined subclasses. Class I and class II deacetylases utilize a zinc-dependent mechanism. The sirtuin histone deacetylases belong to class III and are NAD-dependent enzymes.Valproic Acid: A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.UkraineDirected Tissue Donation: Tissue, organ, or gamete donation intended for a designated recipient.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Aspergillosis: Infections with fungi of the genus ASPERGILLUS.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Terminology as Topic: The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.Transplantation Conditioning: Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.Faculty, Medical: The teaching staff and members of the administrative staff having academic rank in a medical school.Gastroenterology: A subspecialty of internal medicine concerned with the study of the physiology and diseases of the digestive system and related structures (esophagus, liver, gallbladder, and pancreas).Privacy: The state of being free from intrusion or disturbance in one's private life or affairs. (Random House Unabridged Dictionary, 2d ed, 1993)Pediatrics: A medical specialty concerned with maintaining health and providing medical care to children from birth to adolescence.Confidentiality: The privacy of information and its protection against unauthorized disclosure.Computer Security: Protective measures against unauthorized access to or interference with computer operating systems, telecommunications, or data structures, especially the modification, deletion, destruction, or release of data in computers. It includes methods of forestalling interference by computer viruses or so-called computer hackers aiming to compromise stored data.Celiac Disease: A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Journal Impact Factor: A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.Informed Consent: Voluntary authorization, by a patient or research subject, with full comprehension of the risks involved, for diagnostic or investigative procedures, and for medical and surgical treatment.Publishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.

Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. (1/440)

BACKGROUND AND PURPOSE: Human umbilical cord blood cells (HUCBC) are rich in stem and progenitor cells. In this study we tested whether intravenously infused HUCBC enter brain, survive, differentiate, and improve neurological functional recovery after stroke in rats. In addition, we tested whether ischemic brain tissue extract selectively induces chemotaxis of HUCBC in vitro. METHODS: Adult male Wistar rats were subjected to transient (2-hour) middle cerebral artery occlusion (MCAO). Experimental groups were as follows: group 1, MCAO alone (n=5); group 2, 3x10(6) HUCBC injected into tail vein at 24 hours after MCAO (n=6) (animals of groups 1 and 2 were killed at 14 days after MCAO); group 3, MCAO alone (n=5); group 4, MCAO injected with PBS at 1 day after stroke (n=8); and group 5, 3x10(6) HUCBC injected into tail vein at 7 days after MCAO (n=5). Rats of groups 3, 4, and 5 were killed at 35 days after MCAO. Behavioral tests (rotarod and Modified Neurological Severity Score [mNSS]) were performed. Immunohistochemical staining was used to identify cells derived from HUCBC. Chemotactic activity of ischemia brain tissue extracts toward HUCBC at different time points was evaluated in vitro. RESULTS: Treatment at 24 hours after MCAO with HUCBC significantly improved functional recovery, as evidenced by the rotarod test and mNSS (P<0.05). Treatment at 7 days after MCAO with HUCBC significantly improved function only on the mNSS (P<0.05). Some HUCBC were reactive for the astrocyte marker glial fibrillary acidic protein and the neuronal markers NeuN and microtubule-associated protein 2. In vitro, significant HUCBC migration activity was present at 24 hours after MCAO (P<0.01) compared with normal brain tissue. CONCLUSIONS: Intravenously administered HUCBC enter brain, survive, migrate, and improve functional recovery after stroke. HUCBC transplantation may provide a cell source to treat stroke.  (+info)

Listeriosis in recipients of allogeneic blood and marrow transplantation: thirteen year review of disease characteristics, treatment outcomes and a new association with human cytomegalovirus infection. (2/440)

Listeriosis is uncommon in recipients of allogeneic blood, marrow and organ transplantation. Six patients with systemic Listeria monocytogenes infection during 1985-1997 at Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center are described. In two male and four female patients, the median duration from transplantation to isolation of L. monocytogenes was 62.5 (range 29 to 821) days. Among five allogeneic marrow transplant recipients, four (80%) received HLA antigen matched, T cell-depleted grafts from three unrelated and a single related donor. One patient underwent mismatched-related marrow graft transplant. Cord stem cell transplantation was performed in a single patient. Two required therapy for graft-versus-host disease (GVHD). The 13 year incidence of systemic Listeria infections was 0.47 percent. All six presented with fever (>39 degrees C), and L. monocytogenes bloodstream invasion. Mental status changes and meningioencephalitis were observed in two (33.3%). A concurrent primary opportunistic infection was present in five individuals (83.3%), and four (80%) were being treated for acute human cytomegalovirus (HCMV) viremia. Sixty-six percent responded to therapy and two died from unrelated, non-listeric causes. Systemic listeriosis was uncommon in our high-risk allogeneic blood and marrow transplantation population, and response to therapy with parenteral ampicillin and gentamicin was excellent. The association between primary HCMV reactivation and subsequent listeric infection emphasizes the significance of HCMV-related dysfunction in hosts' cellular immune responses, especially in the setting of allogeneic transplantation.  (+info)

Human herpesvirus-6 encephalitis after unrelated umbilical cord blood transplant in children. (3/440)

Three children developed human herpesvirus-6 (HHV-6), variant B encephalitis after unrelated umbilical cord blood transplant, in a single center. They developed clinical manifestations of encephalitis around day 17 post transplant. Impairment of consciousness, incoherent speech, episodic focal pruritus, motor weakness, convulsions and severe hyponatremia were features at presentation. Radiological investigation of brain ranged from unremarkable to extensive white matter and meningeal lesions. Diagnosis was established by the presence of HHV-6 DNA in cerebrospinal fluid (CSF). Retrospective analyses of plasma revealed the presence of viral DNAemia prior to the onset of disease in two subjects. Treatment with ganciclovir or foscarnet was given. Two subjects did not achieve engraftment and died of other transplant-related complications on day 38 and 56 post-transplant, respectively. One subject achieved disease-free survival for more than 1 year with a satisfactory neurological outcome. In conclusion, HHV-6 encephalitis is not uncommon among patients undergoing umbilical cord blood transplantation. It is worth conducting further studies on early diagnosis and optimal management of this potentially fatal disease.  (+info)

Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantation. (4/440)

The prognosis for blastic natural killer (NK) cell lymphoma is generally dismal. We report a patient who was successfully treated with unrelated cord blood transplantation (UCBT). A 15-year-old boy was diagnosed as having blastic NK cell lymphoma in the cervical lymph nodes. Autologous peripheral blood stem cell transplantation was performed on achieving a complete remission. However, the disease recurred in the bone marrow 6 months later. Chemotherapy induced a second remission and the patient received UCBT with a conditioning regimen consisting of total body irradiation, thiotepa and cyclophosphamide. Chronic GVHD of the lung occurred, but it was well controlled with steroids. At the time of writing, he remains in remission 18 months after UCBT with an excellent performance status. UCBT may be an option for patients with blastic NK cell lymphoma.  (+info)

Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. (5/440)

In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4(+) T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.  (+info)

A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation. (6/440)

An 11-month-old boy with acute lymphoblastic leukemia (ALL) underwent umbilical cord blood transplantation (CBT) from an unrelated donor after a first complete remission. Despite the prophylactic use of low molecular weight heparin, prostaglandin E1 and ursodeoxycholic acid, hepatic veno-occlusive disease (VOD) occurred on the 29th day after CBT. Furthermore, neither defibrotide nor antithrombin-III improved the hepatic coma and coagulopathy due to the hepatic VOD. On the 42nd day after CBT, he underwent living related liver transplantation (LRLT) with a left lateral segment graft from his father. He received tacrolimus for the prevention of rejection and graft-vs.-host disease (GVHD) and also received aggressive antifungal and antiviral prophylaxis. Although he showed signs of acute rejection on postoperative days 5 and 10, the postoperative course was uneventful in general. At present, 17 months after LRLT, the patient shows stable liver function and no signs of either GVHD or a relapse of ALL. In conclusion, LRLT can be seen as a feasible option for the treatment of a hepatic VOD after CBT, though aggressive prophylaxis for infection and the anticipation of acute rejection are of importance.  (+info)

"Saviour siblings". (7/440)

The Victorian Infertility Treatment Authority has given permission to allow tissue typing in combination with preimplantation genetic diagnosis. This is a new application of IVF. Not only will it allow parents to select an embryo free from serious genetic disease it will allow them to simultaneously select for a match so that the umbilical cord blood of the resulting baby can provide stem cells to treat an existing sibling who has a disease.  (+info)

Induction of graft-versus-host disease and a graft-versus-leukemia effect using ubenimex in a patient with infantile leukemia relapsing after an unrelated cord blood transplant. (8/440)

A 20-month-old boy with infantile leukemia was treated with total body irradiation, etoposide, cyclophosphamide and unrelated cord blood transplantation with a one-antigen mismatch. He relapsed on day 100 and achieved remission after ubenimex administration, and also developed chronic graft-versus-host disease of the skin. He remained in remission for 22 months with repeated courses of ubenimex. Ubenimex may be an alternative to donor lymphocyte transfusion and may be useful for the treatment of a patient who has relapsed after cord blood transplantation.  (+info)

*Cord blood

... is used the same way that hematopoietic stem cell transplantation is used to reconstitute bone marrow following ... The cord blood is composed of all the elements found in whole blood. It contains red blood cells, white blood cells, plasma, ... Collected cord blood is cryopreserved and then stored in a cord blood bank for future transplantation. Cord blood collection is ... Cord blood is being used to get stem cells with which to test in people with type 1 diabetes mellitus. The stem cells from ...

*Hematopoietic stem cell transplantation

... or umbilical cord blood. It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a ... Peripheral blood stem cells are now the most common source of stem cells for HSCT. They are collected from the blood through a ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... Umbilical cord blood is obtained when a mother donates her infant's umbilical cord and placenta after birth. Cord blood has a ...

*Cord blood bank

... unless there is a family member with a current or potential need to undergo a stem cell transplantation. The American Academy ... However, cord blood stem cells (hematopoietic stem cells) are not embryonic stem cells (pluripotent stem cells). Cryo-Cell ... Cord blood stem cells are blood cell progenitors which can form red blood cells, white blood cells, and platelets. This is why ... Since then, cord blood has become increasingly recognized as a source of stem cells that can be used in stem cell therapy. ...

*Reticular dysgenesis

Transplantation of stem cells are taken from the bone marrow, peripheral blood or umbilical cord of healthy, matched donors. ... Hematopoietic stem cells give rise to blood cells. Differentiation and proliferation of hematopoietic stem cells require a lot ... Stem cells are taken from an affected child's blood or bone marrow. Then in laboratory conditions the stem cells are ... Hematopoietic Stem Cell Transplantation (HSCT) involves intravenous infusion of stem cells to those who have either a damaged ...

*Myelokathexis

... is amongst the diseases treated with bone marrow transplantation and cord blood stem cells.[citation needed] WHIM ... Myelokathexis is a congenital disorder of the white blood cells that causes severe, chronic leukopenia (a reduction of ... circulating white blood cells) and neutropenia (a reduction of neutrophil granulocytes). The disorder is believed to be ... Blood. 95 (1): 320-327. PMID 10607719. Hord, JD; Whitlock, JA; Gay, JC; Lukens, JN (Sep-Oct 1997). "Clinical features of ...

*LifeSouth Community Blood Centers

... and stores umbilical cord blood for the purpose of clinical cures and basic research in the field of stem cell transplantation ... cord blood collection and processing, distribution of the cord blood units, and evaluation of transplant outcomes. "Revenue ... cord blood, organ and tissue. The Foundation works with blood centers, organ procurement organizations, marrow registries and ... LifeCord participates in the network of public cord blood banks affiliated with the National Marrow Donor Program's Be The ...

*Bone Marrow Donors Worldwide

Search & Match tool: The BMDW provides a fast preliminary search tool to find the best matched stem cell donor or cord blood ... The tool is primarily intended for use by professionals in the field of stem cell transplantation with profound knowledge of ... The purpose of BMDW still remains the same, to collect the HLA phenotypes of volunteer stem cell donors and cord blood units ... BMDW's mission is to create a comprehensive, fair, and equitable global list of unrelated stem cell donors and cord blood ...

*Cells4Life

Jane Dreaper (13 May 2005). "Concern over cord blood banking". BBC News. Retrieved 24 March 2016. "New cord blood stem cell ... "Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For ... It procures, processes and stores human umbilical cord blood and tissue samples that may be used for stem cell treatments. ... "5 things to think about when banking your baby's stem cells". Cord Blood Aware. 29 January 2016. Retrieved 24 March 2016. ...

*Regenerative medicine

... and not pluripotent stem cells (such as embryonic stem cells, which can differentiate into any type of tissue). Cord blood has ... hematopoietic cell transplantation stem cell transplantation (4th ed.). Oxford: Wiley-Blackwell. ISBN 9781444303537. Haller M J ... Along with cord blood, Wharton's jelly and the cord lining have been explored as sources for mesenchymal stem cells (MSC), and ... Any such potential beyond blood and immunological uses is limited by the fact that cord cells are hematopoietic stem cells ( ...

*Juvenile myelomonocytic leukemia

Only Hematopoietic Stem Cell Transplantation (HSCT), commonly referred to as a bone marrow or (umbilical) cord blood transplant ... high white blood cell count in blood), absolute monocytosis (high monocyte count in blood), anemia (low red blood cell count in ... Immature granulocytes and nucleated red cells in the peripheral blood. White blood cell count >10 x 109/L. Clonal chromosomal ... The only treatment that has resulted in cures for JMML is stem cell transplantation, also known as a bone marrow transplant, ...

*Induced pluripotent stem cell

... endothelial stem cells (to form lining of blood vessels) from umbilical cord blood; and mesenchymal stem cells (to form ... A proof-of-concept of using induced pluripotent stem cells (iPSCs) to generate human organ for transplantation was reported by ... 2 July 2010). "Reprogramming of human peripheral blood cells to induced pluripotent stem cells". Cell stem cell. 7 (1): 20-4. ... Embryonic cord-blood cells were induced into pluripotent stem cells using plasmid DNA. Using cell surface endothelial/pericytic ...

*Relicord

... A offer stem cell enriched cord blood repository services as well as stem cell enriched cord blood for transplantation ... Under ReliCord S the stored cord blood stem cells can be used for haematopoetic stem cell transplantation for family members ... culturing of mesenchymal stem cells and storage of cord tissue with 15 million stem cells. Before storage the cord blood is ... The stem cell enriched cord blood is then cryo-preserved at the repository at a temperature of minus 196 degrees Celsius. Stem ...

*CCR5

"Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation". Blood. 117 (10): 2791-9. doi:10.1182/blood- ... StemCyte began collaborations with Cord blood banks worldwide to systematically screen Umbilical cord blood samples for the ... "Progress toward curing HIV infection with hematopoietic cell transplantation". Stem Cells and Cloning. 8: 109-16. doi:10.2147/ ... "Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation". The New England Journal of Medicine. 360 (7): 692- ...

*Stem cell

16 December 2013 Why Perform a Stem Cell Transplant? Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation ... Stem cells can also be taken from umbilical cord blood just after birth. Of all stem cell types, autologous harvesting involves ... mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, dental pulp stem cell, etc.). Muse cells (multi- ... Cell bank Human genome Meristem Partial cloning Plant stem cell Stem cell controversy Stem cell marker Shinya Yamanaka Tuch BE ...

*Testicular cancer

Treatment options may include surgery, radiation therapy, chemotherapy, or stem cell transplantation. Even in cases in which ... Sex cord/Gonadal stromal tumors Leydig cell tumor Sertoli cell tumor Lipid rich variant Scleriosing variant Large cell ... This is because the lymphatic system of the scrotum, through which white blood cells (and, potentially, cancer cells) flow in ... mixed types Mixed Germ Cell and Sex Cord/Gonadal Stromal Tumors Gonadoblastoma Germ cell-sex cord/gonadal stromal tumor, ...

*Umbilical cord

"Cord Blood Banking for Potential Future Transplantation". "Cord blood yields 'ethical' embryonic stem cells.", Coghlin A. New ... to freeze for long-term storage at a cord blood bank should the child ever require the cord blood stem cells (for example, to ... 2005). "Anti-inflammatory effects of human cord blood cells in a rat model of stroke". Stem Cells Dev. 14 (5): 595-604. doi: ... Cord Blood for Neonatal Hypoxic-Ischemic Encephalopathy, Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy Study ...

*Peripheral stem cell transplantation

"Stem Cell Transplant (Peripheral Blood, Bone Marrow, and Cord Blood Transplants)". Retrieved 4 March 2012. "Peripheral Blood ... Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support", is a method of replacing blood- ... "Peripheral blood stem cells for allogeneic transplantation: a review". Stem cells (Dayton, Ohio). 19 (2): 108-17. doi:10.1634/ ... CD34+ cells) yield. Immature blood cells hematopoietic stem cells in the circulating blood that are similar to those in the ...

*City of Hope National Medical Center

... peripheral blood stem cells collected by apheresis, and umbilical cord stem cells. By 2016, this has grown to over 13,000 stem ... On January 13, 2011, City of Hope performed its 10,000th hematopoietic stem cell transplantation, which includes transplants of ... contract to facilitate stem cell research from laboratory to clinical study; focus on development and manufacture of stem cell ... Joy, Darrin S. (2009-12-14). "City of Hope receives $17 million for islet and stem cell informatics". City of Hope - Hope News ...

*CLEC11A

... stem cell factor and rhIL-4 stimulate differentiation and proliferation of CD3+ cells from umbilical cord blood and CD3+ cells ... "Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation". Bone Marrow ... "In vitro differentiation of endothelial cells from AC133-positive progenitor cells". Blood. 95 (10): 3106-12. PMID 10807776. ... Hollenbeck ST, Sakakibara K, Faries PL, Workhu B, Liu B, Kent KC (August 2004). "Stem cell factor and c-kit are expressed by ...

*Wharton's jelly

... is therefore a potential source of adult stem cells (also see the more common method of storing cord blood). ... "Wharton's Jelly Transplantation Improves Neurologic Function in a Rat Model of Traumatic Brain Injury". Cell Mol Neurobiol. 35 ... Stem Cells. 2003;21(1):50-60. Wharton's Jelly, Hair Follicles New Sources of Adult Stem Cells, Studies Find StemCellNews.com, ... "Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes". Cell Immunol. ...

*Healthcare Systems Bureau

Bill Young Cell Transplantation Program and National Cord Blood Inventory, HRSA helps make possible blood stem cell transplants ... Stem cells for transplant come from adult volunteer donors and umbilical cord blood units donated to public cord blood banks. ... "What you must know about umbilical cord stem cells". U.S. Government Accountability Office, Report to Committees: Drug Pricing ... The program recruits adult volunteer donors, helps member cord blood banks collect and list additional units, and supports ...

*David Burrowes

Sickle Cell and Thalassaemia, Stem Cell Transplantation (Vice-Chair), Sustainable Relationships (Secretary), Voice UK and Youth ... umbilical cord blood banking, treatment and research in his Parliament biography. Burrowes was a member of a number of All ... and Stem Cell Transplantation. David is also an officer of the following APPGs - Cyprus, Human Trafficking, Religious Education ... and Stem Cell Transplantation. David is also an officer of the following APPGs - Cyprus, Human Trafficking, Religious Education ...

*King Hussein Cancer Center

Sarhan, a former professor of pediatrics in the Bone Marrow and Stem Cell Transplantation Program at Duke University, was an ... The program oversees both matched allogeneic and autologous transplants and performs transplants utilizing cord blood, making ... He founded KHCC's bone marrow transplantation (BMT) program in 2003, a program which has become one of the largest and most ...

*Royan Institute

... induced pluripotent stem cells, germ line stem cells, adult stem cells, cancer stem cells, and cord blood stem cells. The ... or internationally Use of adult stem cells in corneal injuries and myocardial infarction on human Transplantation of stem cells ... founded a Department of Stem Cells in 2002 to establish human embryonic stem cell lines and Induced Pluripotent Stem Cells ( ... one human embryonic stem cell line in International Society of Stem Cell Research Establishment of 6 human embryonic stem cell ...

*Primary immunodeficiency

June 2008). "Stem cell transplantation for primary immunodeficiencies". Bone Marrow Transplant. 41 Suppl 2: S83-6. doi:10.1038/ ... new methods have reduced culture time to 10-12 days by using specific cytokines from adult donors or virus-naive cord blood. ... cell responses to mitogens and allogeneic cells, cytokine production by cells Tests for B cell function: antibodies to routine ... Virus-specific T-Lymphocytes (VST) therapy is used for patients who have received hematopoietic stem cell transplantation that ...

*CD34

... + cell) are normally found in the umbilical cord and bone marrow as hematopoietic cells, or in mesenchymal stem cells, ... of murine hematopoietic stem cells, and can be stimulated and reversed. CD34+ cells may be isolated from blood samples using ... are used to quantify and purify hematopoietic progenitor stem cells for research and for clinical bone marrow transplantation. ... in a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells ...
Banking and Transplantation of Unrelated Donor Umbilical Cord Blood: Status of the National Heart, Lung, and Blood Institute-Sponsored ...
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patients immune system from rejecting the donors stem cells. When the healthy stem cells from an unrelated donor, that do not exactly match the patients blood, are infused into the patient they may help the patients bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the bodys normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening ...
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patients immune system from rejecting the donors stem cells. When the healthy stem cells from an unrelated donor, that do not exactly match the patients blood, are infused into the patient they may help the patients bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the bodys normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening ...
Double-Unit Cord Blood Transplantation Not Superior to Single-Unit in Reducing Risk of Transplant Failure in Children and Young Adults - From the Blood Journals, News, Written in Blood - ASH Clinical News
We describe outcomes of a large series of predominantly small and young children with IMDs belonging to the lysosomal and peroxisomal disorders who underwent transplantation with UCBT at a single center after uniform cytoreduction and were followed for 1 to 11 years (median, 4.6 years). Important variables improving OS significantly were better performance status (P , .001), higher infused CFUs (P = .02), and matched ethnicity between the CBU and the recipient (P = .05). The cumulative incidence (87.1% by day 42) and speed (median, day 22) of neutrophil engraftment was higher and faster than previously reported in large cohort studies.27,28,42 Most patients (97%) achieved and sustained full donor chimerism (, 90%) and normalized enzyme levels where measurable. This high level of donor chimerism is better than those reported in the literature after unrelated bone marrow transplantation. Although detailed, disease-specific outcomes are not fully described in this report; all surviving children ...
Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.
TY - JOUR. T1 - Retention of stemness and vasculogenic potential of human umbilical cord blood stem cells after repeated expansions on PES-nanofiber matrices. AU - Joseph, Matthew. AU - Das, Manjusri. AU - Kanji, Suman. AU - Lu, Jingwei. AU - Aggarwal, Reeva. AU - Chakroborty, Debanjan. AU - Sarkar, Chandrani. AU - Yu, Hongmei. AU - Mao, Hai Quan. AU - Basu, Sujit. AU - Pompili, Vincent J.. AU - Das, Hiranmoy. PY - 2014/10. Y1 - 2014/10. N2 - Despite recent advances in cardiovascular medicine, ischemic diseases remain a major cause of morbidity and mortality. Although stem cell-based therapies for the treatment of ischemic diseases show great promise, limited availability of biologically functional stem cells mired the application of stem cell-based therapies. Previously, we reported a PES-nanofiber based ex vivo stem cell expansion technology, which supports expansion of human umbilical cord blood (UCB)-derived CD133+/CD34+ progenitor cells ~225 fold. Herein, we show that using similar ...
In a new peer-reviewed article published by the Journal of Translational Medicine, scientists from Beike Biotechnology,Chinas leading stem cell research and regenerative medicine company, and Medistem, Inc.,reported positive safety data in 114 patients who were treated by doctors at Nanshan Affiliated Hospital of Guangdong Medical College (Shenzhen Nanshan Hospital) in Shenzhen using Beikes proprietary cord blood stem cell transplantation protocol.
We studied the effect of the inter-unit HLA match on outcomes of double UCB transplantation for acute leukemia and did not find an association between inter-unit HLA-mismatch and outcomes. Specifically, there were no differences in hematopoietic recovery, acute GvHD or survival, demonstrating that inter-unit HLA-match is not relevant when selecting UCB units for double UCB transplantation for acute leukemia. The only unit characteristic associated with neutrophil recovery was cell dose. Transplantations of UCB units with a combined infused TNC 4×107/kg or more was associated with faster neutrophil recovery, but infused TNC was not associated with survival or non-relapse mortality. There were no differences in engraftment of the dominant and non-dominant units based on inter-unit HLA match or unit TNC within the first month after transplantation. Our observations are not in keeping with a single report of early engraftment of the non-dominant UCB unit when the cell dose of the dominant unit was ...
Our goal is to increase the number of immature umbilical cord blood stem cells (UCBSCs) for hematopoietic transplantation. Towards this goal, our lab adapted a culture technique to grow immature CD133+ UCBSCs (CD133+ cells). Although CD133+ cells proliferate rapidly in culture, a minority self-renew and remain CD133+, while a majority differentiate and become CD133-. Therefore, new strategies to identify and grow immature UCBSCs are important. Since little is known about signally mechanisms regulating self-renewal and differentiation of UCBSCs, we sought insight from embryonic stem cell (ESC) literature to guide our studies. \r\nTo identify a population of UCBSCs that grow without differentiating, we focused on Oct-4, a transcription factor essential for self-renewal in ESCs that we previously reported expression in UCBSCs. During our studies, new challenges in the field arose. Two isomers of Oct-4 were discovered, Oct-4A and Oct-4B 3, in which only Oct-4A conferred the ability of ESCs to ...
Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University
ORLANDO, Florida, January 30 /PRNewswire/ -- John Wagner, M.D., recognized as a leader in the field of cord blood stem cell transplantation, has joined the team at CORD:USE Cord Blood Bank. Dr. Wagners extensive experience and knowledge in transplant medicine and stem cell biology will provide a significant contribution to CORD:USE.
TY - JOUR. T1 - Concurrent acute necrotizing adenovirus hepatitis and enterocolitis in an adult patient after double cord blood stem cell transplant for refractory. AU - Disease, Crohns. AU - Lo, Amy A.. AU - Lo, Edward C.. AU - Rao, M. Sambasivia. AU - Yang, Guang Yu. PY - 2015/5/1. Y1 - 2015/5/1. N2 - It has been recently recognized that adenovirus is a pathogen with high morbidity and mortality among immunocompromised patients, particularly after solid organ or stem cell transplant. Confluent necrotizing hepatitis secondary to adenovirus infection alone or together with other organ involvement is extremely rare. There are only 32 cases of confluent necrotizing hepatitis reported in adults since 1960 and most occur after iatrogenic immunosuppression for bone marrow or solid organ transplantation or in other states of immunosuppression, including acquired immunodeficiency syndrome or chemotherapy treatment. We present the first case of concurrent adenovirus-induced necrotizing hepatitis and ...
The main purpose of this investigational (not approved by the FDA) Phase I research is to test whether transplantation of umbilical cord blood cells can
Our data indicate that UCBT is an excellent option for children with hereditary bone marrow failure syndromes when the donor is an HLA-matched sibling donor. Our results are in agreement with those of a previously published analysis which compared outcome of patients undergoing HLA-identical sibling UCBT with that of HLA-identical sibling bone marrow transplant recipients and showed similar overall survival in children with malignant and non-malignant diseases.16 Banks of related cord blood have been established; they are not, however, sufficiently developed despite the excellent results observed not only in marrow failure but also in other hereditary disorders such as hemoglobinopathies, metabolic disorders and congenital immune deficiencies.17,18 Another factor in favor of freezing cord blood cells from an HLA-identical sibling is the absence of risk for the donor.. An important observation is that the risk of graft failure after unrelated UCBT was high in this cohort of patients. The risk of ...
Background: Measures were introduced in both the House and Senate to establish a National Cord Blood Stem Cell Bank Network.. Umbilical cord blood stem cells are obtained from the blood contained in the delivered placenta and umbilical cord, which are normally discarded after childbirth. Obtaining these stem cells presents no inherent moral concerns. Through freezing they can be preserved for many years.. According to findings presented in the House measure, cord blood stem cell transplants can be used for bone marrow reconstitution to treat malignancies such as leukemia and lymphoma, genetic disorders such as sickle cell anemia, and acquired diseases. The findings also claim that cord blood stem cells do not have to be matched as closely as bone marrow transplants. This means patients will be more likely to find a suitable unrelated cord blood donor than a matched bone marrow donor. Supporters say a network of at least 150,000 units of ethnically balanced cord blood donors would provide ...
Cell dose is a critical determinant of outcomes in unrelated cord blood (CB) transplantation. We investigated a strategy in which CB units should contain at least 2 × 107 total nucleated cells/kg of recipient weight, otherwise a second unit had to be added. We report the results of a study that was prematurely closed owing to toxicity. Patients with advanced hematologic malignancies without a human leukocyte antigen-matched sibling or unrelated donor were eligible. Conditioning regimen consisted of fludarabine and 12 Gy of total body irradiation (n=11), or melphalan (n=4), with antithymocyte globulin. Graft-versus-host disease prophylaxis was tacrolimus and methotrexate. Fifteen patients with acute leukemia (n=9), chronic myelogenous leukemia (n=2), multiple myeloma (n=2) and lymphoma (n=2) were treated; 60% had relapsed disease at transplantation. Three patients received double CB transplants. The 100-day and 1-year treatment-related mortality rates were 40 and 53%, respectively. Median time to
ATLANTA —Twelve percent of adults with acute myeloid or acute lymphoblastic leukemia who received umbilical cord blood transplantation experienced graft failure, according to a large European retrospective study presented at the ASH Annual Meeting and Exposition.“Our aim was to assess the outcomes of patients with acute leukemia who experience graft failure after umbilical cord blood
... ORLANDO Fla. Jan. 30 /- John Wagner M.D. recogniz... Were honored and fortunate to have him as a member of ourdistinguis...Dr. Wagner is internationally recognized as an expert in the field of...Dr. Wagner has played a considerable role in the development andexpan...,CORD:USE,Cord,Blood,Bank,Announces,the,Addition,of,Dr.,John,Wagner,,a,Pioneer,in,the,Use,of,Umbilical,Cord,Blood,Stem,Cells,,to,Its,Scientific,Advisory,Board,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
This clinical trial studies intra-osseous donor umbilical cord blood and mesenchymal stromal cell co-transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy and total-body irradiation before a co-transplant of donor umbilical cord blood and mesenchymal stromal cells into the bone (intra-osseous) helps stop the growth of cancer cells. It may also stop the patients immune system from rejecting the donors stem cells. The donated stem cells may replace the patients immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).
Haematopoietic stem cell transplants have been performed for more than 50 years and have been used to treat more than 80 life-threatening diseases
Stem cells hold the promise of treatments and cures for more than 70 major diseases.Dating back to the worlds first successful bone marrow transplant in 1968, the University of Minnesota Medical School has been, and continues to be, a leader in stem cell research and regenerative medicine-a field of innovative therapies that enable the body to heal itself.Now with new discoveries being made, were working on cures for everything from diabetes to dementia. The Medical Schools blood and marrow transplant research has a legacy of changing perspectives around what is medically possible for children battling some of the worlds most complex, life-threatening diseases. Beyond the first successful bone marrow transplant (BMT) in the world, the Medical School has a history of firsts, including:The first transplant to treat a patient with lymphoma (1975)The first transplant to treat an inherited metabolic disease (1982)The first double umbilical cord blood transplant (1999)The first umbilical cord blood
Tens of thousands of patients need bone marrow transplants (BMT) every year, some for bone marrow (BM) cancers and some for inherited diseases such as sickle cell anemia and thalassemia, but many lack a BM donor. African Americans, Asian Americans, and people of Hispanic descent are more likely than others to lack a stem cell donor. BMTs provide hematopoietic (blood) stem and progenitor cells (HS/PCs) that replace the patients diseased BM with healthy BM. The new BM provides all the circulating blood cells throughout life. Many BMTs use HS/PCs that do not come from the BM. One such other source is umbilical cord blood (UCB). UCB HS/PCs have many advantages over other HS/PC sources (i.e., BM or peripheral blood). For example, we can easily obtain UCB HS/PCs without any risk to the donor, and we can keep the cells stored in freezers to be available when a patient needs them. However, most UCB samples contain too few HS/PCs to be used to treat people. Expanding the number of HS/PCs in UCB ...
Aarogya.com is Leading comprehensive health portal. This site has covered almost all the medical specialties and give useful information on various diseases.
Cord blood stem cell application is increasing a faster rate than other stem cell techniques because of its efficient and cost effective treatment p
Buy or Rent Cord Blood Stem Cells Medicine as an eTextbook and get instant access. With VitalSource, you can save up to 80% compared to print.
A new syndrome characterized by watery diarrhea has been identified in a group of patients who underwent cord blood stem cell transplantation.
Purpose: Survival of acute leukemia (AL) patients following umbilical cord blood transplantation (UCBT) is dependent on an array of individual features. Integrative models for risk assessment are lacking. We sought to develop a scoring system for prediction of overall survival (OS) and leukemia-free survival (LFS) at 2 years following UCBT in AL patients.. Experimental Design: The study cohort included 3,140 pediatric and adult AL UCBT patients from the European Society of Blood and Marrow Transplantation and Eurocord registries. Patients received single or double cord blood units. The dataset was geographically split into a derivation (n = 2,362, 65%) and validation set (n = 778, 35%). Top predictors of OS were identified using the Random Survival Forest algorithm and introduced into a Cox regression model, which served for the construction of the UCBT risk score.. Results: The score includes nine variables: disease status, diagnosis, cell dose, age, center experience, cytomegalovirus ...
U.S. District Court Judge Gregory M. Sleet ended the stem cell patent suit by PharmaStem Therapeutics, Inc. against CorCell, Inc. and numerous private umbilical cord blood banks for infringement of its patents 5,004,681 and 5,192,553. Judge Sleet stated that, There was no legally sufficient evidentiary basis for a reasonable jury to find that all, or any specific number, of the defendants cord blood units infringe the 681 patent. This judgment follows a Sept. 14, 2004 ruling by Judge Sleet stating that the defendants did not infringe on the 553 patent, the first of two PharmaStem patents in question. The earlier judgment overturned a $7 million award to PharmaStem. Earlier, the Court held that CorCell is not, and cannot be, liable for patent infringement because they do not sell, or offer for sale umbilical cord blood. The Federal Courts decision decisively rejects PharmaStems effort to prevent CorCell from processing and storing umbilical cord blood for families. The implication of this ...
Groundbreaking research has led to the first clinical trial to evaluate the safety of cord blood stem cell treatments for hearing loss. According to a study published in Cell Transplantation, animal subjects treated with cord blood stem cells showed significant healing to the damaged sensory hair cells and neurons in the inner ear. Dr. James Baumgartner, pediatric neurosurgeon, and colleagues at Childrens Memorial Hermann Hospital in Houston will launch the first FDA-regulated clinical trial evaluating the use of cord blood stem cell treatments for children with hearing loss.. ...
TY - JOUR. T1 - A "No-wash" Albumin-Dextran Dilution Strategy for Cord Blood Unit Thaw. T2 - High Rate of Engraftment and a Low Incidence of Serious Infusion Reactions. AU - Barker, Juliet N.. AU - Abboud, Michelle. AU - Rice, Robert D.. AU - Hawke, Rebecca. AU - Schaible, Allison. AU - Heller, Glenn. AU - La Russa, Vincent. AU - Scaradavou, Andromachi. PY - 2009/12/1. Y1 - 2009/12/1. N2 - Preparation of cord blood (CB) units for infusion by albumin-dextran dilution without centrifugation may be advantageous for adult patients to minimize cell loss and, unlike a bedside thaw, is still conducted in the controlled laboratory environment. Therefore, we studied CB transplantation (CBT) using this technique in 54 consecutive CBT recipients ,20 kg. Patients (median age=42 years [range: 7-66 years]; median weight=71 kg [range: 24-109]) were transplanted for high-risk hematologic malignancies with myeloablative (n=35) or nonmyeloablative (n=19) conditioning and 4-6/6 human leukocyte antigen ...
Stem cells are primitive, non-specialised cells characterized by their limitless potential to proliferate and their unique ability to differentiate into specialised cells whereby tissues are formed. Their properties have been used to renew or replace damaged cells. Stem cells can be retrieved, among others, from the umbilical cord blood.. Bone marrow was the primary source of stem cells (bone marrow transplantation involves transplanting stem cells derived from the bone marrow), whereas nowadays, the umbilical cord blood stem cells are more frequently applied for therapeutic uses. Other sources include the peripheral blood drawn from donors who underwent pharmacological mobilisation.. Each living organism, through the course of its life, systematically produces new cells which subsequently mature and differentiate into more specialised cells. Eventually, these cells perish after a specific period of time, as inscribed in their genetic code. Specific stem cells are cells which directly replace ...
snip}. {snip} Every year in the United States, about 12,000 people up to age 74 need bone marrow or umbilical cord blood transplants for survival.. Bone marrow donors go through one of two procedures when theyre found to be a match: a peripheral blood stem cell process, where the donor has a needle inserted into an arm that collects stem cells; or a surgical procedure, where the donor is put under anesthesia and then has bone marrow extracted from the lower back region. Most donors go through the first process. Each process often leaves the donor slightly bruised, but thats about the worst of it.. The likelihood of a person matching with an available donor on the Be The Match registry ranges from 19 to 80 percent, depending on their ethnicity, according to worldwide data from the organization.. {snip} In recent years, there have been numerous reports that the number of Black bone marrow donors is too low. Black people seeking a bone marrow transplant have about a 23 percent chance of finding ...
In this show Prof. Roger Pedersen, from Cambridge University, joins us to discuss what are stem cells, what is their role in the developing embryo, and how can they be used to repair or replace damaged tissues, and Dr Huseyin Mehmet, from Imperial College London, discusses how he is developing therapies for cerebral palsy based on stem cell repair. Also joining us is Soren Muller Bested, from Singapores umbilical cord blood stem cell bank, CordLife, to discuss how discarded umbilical cords of new born babies are a rich source of stem cells.
As part of her acute myeloid leukemia (AML) treatment, Erika Evans was supposed to undergo a stem cell transplant . But she couldn't find a stem cell donor match and instead received an umbilical cord blood transplant.
1995 Southeasts first umbilical cord blood transplant on an infant and adult performed; states first kidney/pancreas transplant occurs; first gene therapy treatment for brain cancer is done. HIV saliva test, developed by UF veterinarian, is released to the marketplace in several foreign countries; 13-week-old Gary Weems of Pensacola, Fla., has a heart transplant performed at Shands, becoming first infant to undergo a heart transplant in Florida ...
Consider the following example. Many cellular therapeutic laboratories measure viability by staining cells with 7-AAD and flow cytometry. This method is used because, in hematopoietic stem cell processing laboratories, viability can be easily combined with other cell membrane markers, such as CD34 and CD45 in a single flow cytometric enumeration panel. This type of viability testing is regularly used for bone marrow, mobilized peripheral blood and umbilical cord blood stem cell products. Virtually all cord blood products are cryopreserved and can remain in the frozen state for many years. In the example shown in the accompanying graph, 56 cryopreserved cord blood samples were thawed, the mononuclear cells (MNC) fractionated by density gradient centrifugation and tested for viability using 7-AAD as well as measuring the proliferation, cellular functionality and viability using HALO®-96 SPC-QC. The discrepancy between dye exclusion and metabolic viability methodologies is readily apparent. In ...
We had our call today with Dr. Kurtzberg from Duke. Wow! What a lot to take in yet again! This call centered on why she feels we should move forward with the umbilical cord blood transplant even though Dr. Kunkel at Harvard has stated otherwise. If you recall, Dr. Kunkel did the biopsy of the child that had both CGD and DMD. His original findings were positive in that the biopsy had donor Dystrophin in the muscle. If you remember, the lack of Dystrophin is what causes DMD. His last email to me said he continues to research and will for about a year but his new findings were not as promising and he did not think we should consider a transplant based on the data from the biopsy. Dr. Kurtzberg disagrees and feels that we should strongly consider it and this is why. She stated that based on the many diseases and disorders she has treated; she believes this will help Gabe. She also stated that a muscle biopsy (like what Dr. Kunkel did), is not necessarily indicative of what is going on in the rest of ...
Using CB as the graft source provides many advantages; CB units are easy to collect with little or no risk to the mother or newborn. Cord blood units can be rapidly obtained for 80% to 95% of the patients 20 years and older across all races and in almost 100% of younger patients (2). This is particularly advantageous in cases where urgent transplant is mandated. Owing to rapid procurement of CB units, patients can receive CB transplantation (CBT) 4 or 5 weeks earlier than those receiving SCT with a MUD (3). Further, CBT is associated with low risk of infection transmission, requires less-stringent human leukocyte antigen (HLA)-matching criteria, and has relatively lower risk of graft-versus-host disease (GVHD) with preserved graft-versus-malignancy effects. However, it is associated with a greater risk of graft rejection, delayed engraftment, and delayed immune reconstitution, leading to heightened risk of infection or nonrelapse mortality (NRM) (4,5,6,7). Many of the adverse outcomes noted ...
Researchers recently announced the beginning of a FDA-approved clinical trial that uses umbilical cord blood stem cells to cure autism
Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT in Adults with Acute Leukemia in Remission. An Eurocord and ALWP Collaboration Study
Similar to hematopoietic stem cell transplantation (HSCT), disease relapse occurs in unrelated cord blood transplantation (CBT) even the human leukocyte antigen (HLA) alleles are fully matched between donor and recipient. A total of fourteen single nucleotide polymorphisms (SNPs) within the region of major histocompatibility complex (MHC) have been reported previously by Petersdorf et al. (Blood 2013;121:1896-1905) and Piras et al . ( Bone Marrow Transplant. 2014;49:1400-1404) to associate with transplantation determinants post-HSCT. The genomic sequences within 500 base pairs upstream and downstream of the fourteen HSCT-related SNPs were analyzed in this study to investigate whether geneticvariants within the MHC region are associated with disease relapse of unrelated HLA-matched CBT. A panel of seven SNPs was revealed to associate with the risk of relapse after unrelated CBT after analysis of fifty-three donor-recipient pairs. These SNPs included the donor type SNPs of rs2523675 and rs2518028 ...
Alternative Donor Transplantation: Results of Parallel Phase II Trials using HLA-Mismatched Related Bone Marrow or Unrelated Umbilical Cord Blood Grafts
Our data shows that EPCR represents a novel robust marker for expanded human LT-HSCs. In UM171-treated cultures, positivity for EPCR defines a highly HSC-enriched population, which includes most repopulating units. EPCR+ cells are uniformly positive for CD34, CD90, and CD133 and represent a subset of this triple positive population. EPCR is thus the most reliable indication of expanded human CB HSCs, especially in the presence of UM171. The utility of this marker to detect expanded HSCs is less obvious when using fresh CB cells because EPCR levels are lower in these cells (supplemental Figure 15; supplemental Table 6). Nonetheless, nonexpanded CB CD34+EPCR+ cells express HSC surface markers, such as CD90, CD49f, CD133, and ckit (supplemental Figure 16), and can repopulate secondary recipient mice (supplemental Figure 15), suggesting that EPCR also identifies LT-HSCs under these conditions. Using the EPCR marker as a tool to monitor ex vivo HSPC activity, we determined that EPCR-positive cells ...
The use of cord blood cells as hematopoietic stem cell grafts for patients with hematologic malignancies receiving an allogeneic stem cell transplant has been limited to children due to the small number of stem cells present in a single cord blood collection. The result of these limitations has been a high rate of graft failures in adult patients.. To overcome these limitations, researchers from the Icahn School of Medicine at Mount Sinai in New York City treated CD34-positivecells with a combination of histone deacetylase (HDAC) inhibitors and valproic acid. They found that the treated cells produced a greater number of repopulating cells, and established multilineage hematopoiesis in primary, secondary, and tertiary immune-deficient mice. The findings may provide clinical benefit for adults with leukemia, lymphoma, and other blood cancers. The study is published in The Journal of Clinical Investigation.. Study Methods and Results. The researchers treated dividing cord blood CD34-positive cells ...
Results to date of umbilical cord blood transplantation in adult and fully mature adolescent patients are inferior to what is seen in children, due to a
They also found that pleiotrophin increased the numbers of human cord blood stem cells in culture that were capable of engraftment in immune-deficient mice. When they injected pleiotrophin into mice that had received bone marrow-suppressive radiation, they observed a 10-fold increase in bone marrow stem cells compared to untreated mice. "These results confirmed that pleiotrophin induces stem cell regeneration following injury," said Chute. Chute says the finding could lead to broader application of cord blood transplants for the large numbers of patients who do not have an immune-matched donor "Perhaps more importantly, systemic treatment with pleiotrophin may have the potential to accelerate recovery of the blood and immune system in patients undergoing chemotherapy or radiotherapy," he said. Given the potency of the effect of pleiotrophin on stem cell expansion, the authors examined whether pleiotrophin provoked blood-forming cells to become malignant. So far, Chute says they have not seen any ...
Stem cells from cord blood are successfully used today for the current treatment of serious diseases, such as leukemia, lymphomas, tumors of organs, hereditary and acquired disorders of hematopoiesis (blood formation), the immune system and metabolism, using the transplantation of blood-forming stem cells. Cord blood stem cells have already been used in more than 35,000 transplants worldwide to regenerate healthy blood and immune system.. However, modern regenerative treatments are increasing beginning to use various types of stem cells that whole cord blood contains. Cord blood stem cells demonstrated their potential to improve conditions that have no cure today by regenerating damaged tissues and organs, stimulating the body own healing mechanisms and restoring lost functions.. Nearly 1 in 3 people may benefit over their lifetime from regenerative medicine, including therapies for neurological, cardiovascular, autoimmune, orthopedic diseases.. Regenerative medicine therapies may be the best ...
The Stem Cells Portal is a shared platform for the STEM CELLS and STEM CELLS Translational Medicine sister journals, providing up-to-the-minute coverage of the latest research from bench science and developments to clinical applications.. ...
Cordlife India ✔️Over 210 Cities In India✔️Fully automated processing✔️Advanced Cryopreservation✔️Quality Warranty. Book a FREE presentation online.
Achieves landmark milestone within four months of launch of revolutionary banking model In spite of being a highly populated country, India has lacked availability of
Life Cell in India is promoting storage of Cord blood from newborn for Biological health insurance of the child . It recently enrolled its 1000th customer.
Worldwide, there are about 2 billion people suffering from various types of life threatening diseases such as cancer, diabetes, osteopetrosis.
WESTPORT, Feb 17 (Reuters Health) - Simply changing the method of collecting umbilical cord blood for transplantation could double the yield of white blood cells, making cord blood transplantation a more feasible option for adults. "One of the current problems with respect to the clinical use of cord blood stem cells involves the number of hematopoietic precursor cells contained in a single sample, which may not be sufficient for the reconstitution after myeloablative conditioning in adults," Dr. Uriel Elchalal, of the Hadassah Medical Organization, in Jerusalem, Israel, and a multicenter group explain in the January issue of the American Journal of Obstetrics and Gynecology. Use of the technique they describe in the journal, together with ex vivo expansion techniques, "may enhance the possibility of retrieving enough stem cells for successful transplantation in this category of patients." Dr. Elchalal and colleagues compared the yields of three cord blood collection methods in 75 women with ...
A key attribute of automated processing systems such as the AutoXpress® (AXP) Platform is that they efficiently recover mononuclear cells in cord blood collections. In tested samples, the recovery percentage of these stem cells has been calculated at 99.3% efficiency, a 22.7 percent higher yield than the commonly-used Hespan-based cord blood stem cell processing method, which achieved an MNC recovery rate of only 80.9 percent in the largest published Hespan study released in Cord Blood Transplantation.[2]. The Hespan approach requires an additive to facilitate separation of cord blood into layers of plasma, red blood cells, the MNC population of white blood cells and stem cells. The MNCs are then collected by a laboratory technician, which is a manual (not automated) step of the process.[3] The AXP® AutoXpress® System also gained traction because it creates lower and more desirable hematocrit levels than most previous methodologies. [4]. Not surprisingly, the shift toward fully automated ...
The introduction of cord blood (CB) as an alternative graft source for patients without a human leukocyte antigen (HLA) matched donor was a clear breakthrough i...
For over 20 years, umbilical-cord blood has been used in approximately 30,000 hematopoietic stem cell transplants for patients with severe hematologic diseases. Umbilical-cord blood transplants, however, are primarily performed on children and smaller adults since the number of available progenitor cells is limited. Previously, smaller studies suggested that double-unit cord-blood transplants may be advantageous for […]. [Read More] ...
Complementation analysis of a polyhydroxyalkanoate (PHA)-negative mutant of proved that ORF3 in the locus (a 402-bp gene located downstream of the PHA synthase gene) participates in PHA biosynthesis on alkanoic acids, and the ORF3 gene is here referred to as BL21(DE3) carrying under the control of the T7 promoter overexpressed enoyl coenzyme A (enoyl-CoA) hydratase, … Continue reading Complementation analysis of a polyhydroxyalkanoate (PHA)-negative mutant of proved that ORF3. ...
Principal Investigator:AZUMA Eiichi, Project Period (FY):1997 - 1998, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Pediatrics
Sigma-Aldrich offers abstracts and full-text articles by [Emily Charrier, Paulo Cordeiro, Rose-Marie Brito, Michaël Harnois, Samira Mezziani, Sabine Herblot, Françoise Le Deist, Michel Duval].
Most peoples perception is that a traditional bone marrow collection is the only way of collecting blood stem cells, but there are other sources of stem cells that are beneficial to patients. One of these is stimulated or mobilised peripheral blood stem cells (PBSCs) and another is cord blood stem cells or blood stem cells taken from the umbilical cord and placenta after the birth of the baby. In this context "Peripheral" means that the collection is made from veins in your arms. "Stimulated" or "mobilised" means that stem cells are created in higher than normal quantities in the bone marrow and released from the marrow into the blood stream. Under normal circumstances there are too few blood stem cells in the peripheral blood to provide a useful quantity for transplant purposes. However administration of a hormone-like treatment known as G-CSF by a small injection under the skin daily for four days stimulates the bone marrow to produce white cells more quickly and in larger numbers. These are ...
The department has done over 170 transplant since its inception in July 2008. Under Dr. Vijay Ramanan as the head and director the programme has done transplant for various indications successfully. We have done all types of transplant by using varied sources of stem cells from Autologous to Allogenic(Stem cells from peripheral blood, Cord, Haplo-identical). The first centre to do cord blood stem cell transplant from unrelated sources for Thalassaemia, Aplastic Anemia, Inherited Disorders(MPS ...
The department has done over 170 transplant since its inception in July 2008. Under Dr. Vijay Ramanan as the head and director the programme has done transplant for various indications successfully. We have done all types of transplant by using varied sources of stem cells from Autologous to Allogenic(Stem cells from peripheral blood, Cord, Haplo-identical). The first centre to do cord blood stem cell transplant from unrelated sources for Thalassaemia, Aplastic Anemia, Inherited Disorders(MPS ...
Term used to describe a cell with the potential to reproduce itself indefinitely, as well as differentiate into any other embryo tissue cell types. There are also a number of different specialised stem cell definitions: totipotential stem cell (as described above), pluripotential stem cell (capable of forming a number of different cell types), embryonic stem cell (derived from the blastocyst), cord blood stem cell (derived from placental cord blood), mesenchymal stem cell and adult stem cell (derived from adult or postnatal tissue). ...
Term used to describe a cell with the potential to reproduce itself indefinitely, as well as differentiate into any other embryo tissue cell types. There are also a number of different specialised stem cell definitions: totipotential stem cell (as described above), pluripotential stem cell (capable of forming a number of different cell types), embryonic stem cell (derived from the blastocyst), cord blood stem cell (derived from placental cord blood), mesenchymal stem cell and adult stem cell (derived from adult or postnatal tissue). ...
A long history in transplant medicine and now the era of Regenerative Medicine. Cord blood stem cells are doing amazing things. Learn More ...
A long history in transplant medicine and now the era of Regenerative Medicine. Cord blood stem cells are doing amazing things. Learn More ...
A long history in transplant medicine and now the era of Regenerative Medicine. Cord blood stem cells are doing amazing things. Learn More ...
A long history in transplant medicine and now the era of Regenerative Medicine. Cord blood stem cells are doing amazing things. Learn More ...
Sauvageau Lab current projects: HSC self-renewal networks, Ideal cord blood graft, Acute Myeloid Leukemia, Stem Cell determinants
Sauvageau Lab current projects: HSC self-renewal networks, Ideal cord blood graft, Acute Myeloid Leukemia, Stem Cell determinants
The finding means that nearly all patients in need of a transplant can find donors, according to Johns Hopkins scientists who participated in the trials.. Plans are under way for a four-year randomized trial for so-called haploidentical marrow or cord blood transplants in 380 patients to begin late this year or early next year. Many large medical centers, including Johns Hopkins, are expected to participate.. The results of the two studies are good news, Hopkins researchers say, because they address the problem faced by patients when no family members are a complete match for the patients tissue type. Although patients and physicians may then seek donors through national registries, as many as half or more of patients looking for matches in these registries dont find one, and the search can take weeks to months. During this time, a patients disease can progress, notes bone marrow transplant expert Ephraim Fuchs, M.D., who adds that it is especially difficult for minorities to find matches ...
Read the latest updates on new bone marrow transplant therapies at SCCA, including information on treosulfan, gene therapy, immunotherapy, cord blood transplants, and more.
Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.. ...
You are being asked to take part in this study because you are going to have a cord blood transplant and one or more of the cord blood units that are considered by your doctor to be the best choice for your transplant may not meet all the new FDA standards. This study will allow your doctor to use these cord blood units for your transplant. Cord blood units used for transplant on this study must meet standards set by the NMDP. If a cord blood unit meets NMDP standards this means that the cord blood unit is suitable for use. This does not however guarantee that the cord blood units(s) will be successful in treating your disease ...
Front Pharmacol. 2017 Sep 8 Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. Galieva LR1, Mukhamedshina YO1,2, Arkhipova SS1, Rizvanov AA1. Author information Abstract At present there is no effective treatment of pathologies associated with the death of neurons and glial cells which take place as a result of physical trauma or ischemic lesions of the nervous system. Thus, researchers have high hopes for a treatment based on the use of stem cells (SC),
Diabetes mellitus (DM) instigates a cascade of events leading to vascular damage and poor recovery after ischemic stroke. Our previous studies have found that treatment of stroke with bone-marrow-stromal cells initiated at 24h after stroke improves functional recovery in non-DM rats, but not in DM rats. Effective therapy for stroke in the non-DM population may not necessarily transfer to the DM population, prompting the need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke in the DM population. In this study, we hypothesize that treatment of stroke with human umbilical cord blood cells (HUCBCs) promotes neurorestorative effect in DM rats.. Methods: Type one DM (T1DM) was induced with a single injection of streptozotocin (60 mg/kg, ip) to adult male Wistar rats. These rats were subjected to 2h MCAo and were randomized to intravenous injection via tail-vein with: 1) phosphate-buffered saline control; 2) HUCBCs (5x106) at 24 hours after MCAo. A ...
As most parents would like to bank their babies cord blood to help safeguard their families, it is often the cost of cord blood banking that is the one reason why they do not. Most cord blood banks have an upfront fee for collecting, processing and cryo-preserving the cord blood that runs between $1,000 and $2,000. This upfront fee often also includes the price of the kit provided to collect and safely transport the cord blood, the medical courier service used to expedite the kits safe shipment, the testing of the mothers blood for any infectious diseases, the testing of the babys blood for any contamination, and the cost of the first full year of storage. There is then often a yearly fee on the babys birthday for continued storage that runs around $100 to $200 a year ...
As noted, there are different ways to process cord blood, and although the type of processing method doesnt always enter the conversation on cord blood banking, it is a big part of the purity of any cord blood collection. Red blood cells can have a negative impact on a cord blood transfusion. In addition, there is a certain number of stem cells that need to be present in order for the cord blood to be effective in disease treatment. Each processing method has the ability to better reduce the number of RBCs and capture more stem cells. Some processing methods like AutoXpress and Sepax are automated to ensure a level of consistency across all collections. HES is preferred by some banks because it was the original processing method used by most banks and it has a proven track record. You can read more about the different cord blood processing methods here ...
Although cord blood is currently considered discarded human material, it should only be collected for banking with an institutional review board-approved protocol and with signed informed consent from a parent.42,43 Pertinent donor information communicated to the cord blood bank should be kept confidential by the cord blood bank and used only to report important medical information obtained during the cord blood collection, processing, and screening process that is relevant to the safety of the donor and family. If cord blood was collected from a newborn who subsequently developed a genetic, immunologic, or malignant neoplastic disorder, parents should notify the cord blood bank so that the unit is not used for transplantation. All cord blood units banked for potential use should be tested for infectious diseases, similar to those tested in a blood bank, and for hereditary hematologic diseases. The informed consent must contain information pertaining to what tests are to be performed on the cord ...
In the United States, approximately 15 percent of children suffer from low or high-frequency hearing loss.[i] The most common type of hearing loss, especially at high frequencies, is sensorineural. Acquired sensorineural hearing loss results from damage to hair cells in the inner ear (cochlea) and can be caused by illness, medication, noise exposure, birth injury, or head trauma. A childs ability to hear affects the development of language skills, and hearing impairments can lead to poor academic and social development.[ii]. The groundbreaking phase 1 study has a primary objective of determining the safety of using cord blood stem cells in a select pediatric patient population while also assessing whether this approach to treatment improves inner ear function, speech, and language development. Researchers will follow 10 children, ranging in age from 6 weeks to 6 years, who have been diagnosed with acquired hearing loss for less than 18 months and who have their own cord blood unit processed and ...
Umbilical cord blood (UCB) is an alternative hematopoietic stem cell (HSC) source that can ameliorate several diseases through transplantation. The purpose of this project is to analyze clinical studies comparing HSCs from a single cord blood unit (CBU) to HSCs from bone marrow, and to explore methods of increasing limited amounts of HSCs. It was found that UCB transplantation in adults is a viable method when a matched bone marrow transplant cannot be identified. Further clinical studies using two CBUs suggest better engraftment and lower risk of relapse. However, double cord blood transplantation has been faced with the challenge of single unit dominance in most studies. Ex vivo expansion of UCB HSCs is another promising method to overcome limited HSC counts.
It makes more sense to donate】. Base on the current development of biomedical science, AAP discourage saving umbilical cord blood as a "life insurance", because there are no scientific data as of now to support the use of autologous cord blood transplant. Though theoretically possible, we are uncertain whether the theory will become practice at all, or when exactly will this technology be adopted. Most private banks prey on the parents fear of the unknown future, knowing how vulnerable the parents are to the emotional effects of the marketing of cord blood banking. They advertise the many possibility as a reality despite there being a lot of uncertainties still.. Contrarily, there are many successful cases of allogeneic cord blood transplantation. In such cases, the stem cells transplanted are from other individuals. Majority of these stem cell transplants have been done using samples from public banks because a perfect match is not required for cord blood transplantation. This also shows why ...
by APFLI , Feb 2, 2006 , Stem Cell Research & Cloning. www.ClinicalTrials.gov - Amazing list of over 250 grants through NIH; at least half deal with non-embryonic stem cell research. http://www.clinicaltrials.gov/ct/search?term=%22stem+cells%22&submit=Search With patients own cells, heart vessels and tissue show mending http://www.chron.com/cs/CDA/ssistory.mpl/metropolitan/3277225 Check the Score http://stemcellresearch.org/ Diseases Treated Now with Cord Blood Stem Cells http://www.viacord.com/what_diseases_treated.htm Why Cord Blood is the Premier Source of Stem Cellshttp://www.viacord.com/what_why_premier_source.htm Adult & Umbilical Cord Blood Stem Cell Research Breakthroughs, Treatments and Cures as of 4/05 Spinal Cord Injuries - olfactory glial cells from the lining of the patients nose (1,2) or from umbilical cord stem cells (3) Skull Bone Repair - girls own bone and adult stem cells to repair 19 sq in. of her skull (4) Liver Repair - adult stem cells (5) Heart Muscle Regeneration - ...
Newborn Blood Banking stores umbilical cord blood stem cells as an alternative to bone marrow. We store whole blood to maximize the number of stem cells.
Newborn Blood Banking stores umbilical cord blood stem cells as an alternative to bone marrow. We store whole blood to maximize the number of stem cells.
Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication ...
Although pharmacological methods for treating AD have been discovered, none significantly delay the progression of the disease. However, cell transplantation research using animals modeled with AD has indicated that human umbilical cord blood cells (HUCBCs) can ameliorate some cognitive deficits and reduce the effects of the amyloid-beta (Aβ) plaques, one of the physiological hallmarks of AD, comprised of peptides of 36-43 amino acids. However, the role that HUCBCs play in Aβ clearance has yet to be elucidated ...
There are several advantages of using umbilical cord blood stem cells over bone marrow stem cells for transplants (see Table 2). The first advantage is that umbilical cord blood is relatively easy to collect and process. Once considered a substance to be thrown away after a birth, now the cord blood can be easily saved. After it is saved and sent to a storage facility, the cord blood is quickly available for use within days to weeks after processing. In contrast, bone marrow stem cells can take much longer to find a match, collect the sample, and process. The process for bone marrow transplantation can take from weeks to months. The collection process for cord blood is not painful to either mother or child and can be done either prior to or after the delivery of the placenta (Gonzalez-Ryan, VanSyckle, Coyne, & Glover, 2000; Percer, 2009). Bone marrow transplants, on the other hand, require the donor to be hospitalized, anesthetized, and experience postcollection pain and discomfort. Thus, ...
OBJECTIVE We examined the therapeutic strategies for treating mild gastrointestinal (GI) graft-versus-host disease (GVHD) using oral beclomethasone dipropionate (BDP) in 15 Japanese patients based on the donor source. The primary objective was to determine the efficacy and toxicity of oral BDP combined with/without low-dose prednisone (PSL). METHODS Oral BDP was administered with 1 mg/kg/d of PSL in patients undergoing bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT; n=11), and the dose of PSL was tapered off after 22 days. Oral BDP alone was administered in patients undergoing cord blood stem cell transplantation (CBSCT; n=4). The primary endpoint was the rate of treatment success on day 49, as measured according to the improvement or complete resolution of GI symptoms without additional treatment. The secondary endpoints included treatment-related toxicity according to the National Cancer Institute Common Toxicity Criteria version 3.0, the rate of treatment
Diabetes mellitus (DM) is a high risk factor for stroke and leads to more severe vascular and white-matter injury than stroke in non-DM. We tested the neurorestorative effects of delayed human umbilical cord blood cell (HUCBC) treatment of stroke in type-2 diabetes (T2DM). db/db-T2DM and db/+-non-DM mice were subjected to distal middle cerebral artery occlusion (dMCAo) and were treated 3 days after dMCAo with: (a) non-DM + Phosphate buffered saline (PBS); (b) T2DM + PBS; (c) T2DM + naïve-HUCBC; (d) T2DM + miR-126(-/-) HUCBC. Functional evaluation, vascular and white-matter changes, neuroinflammation, and miR-126 effects were measured in vivo and in vitro. T2DM mice exhibited significantly decreased serum and brain tissue miR-126 expression compared with non-DM mice. T2DM + HUCBC mice exhibited increased miR-126 expression, increased tight junction protein expression, axon/myelin, vascular density, and M2-macrophage polarization. However, decreased blood-brain barrier leakage, brain hemorrhage, and miR
American Cancer Society: Bone Marrow and Peripheral Blood Stem Cell Transplants - The American Cancer Society is the nationwide community-based voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives, and diminishing suffering from cancer, through research, education, advocacy, and service. Learn the basics and read the transplant process at this site.. The Bone Marrow Foundation - The mission of The Bone Marrow Foundation is to improve the quality of life for bone marrow and stem cell transplant patients and their families by providing financial aid, education and emotional support.. BMT InfoNet - Blood & Marrow Transplant Information Network is a not-for-profit organization dedicated exclusively to serving the needs of persons facing a bone marrow, blood stem cell or umbilical cord blood transplant. Here you will find support services, a drug database and more.. Cancer.Net: Understanding Bone Marrow and Stem Cell ...
Chatchada Karanes, M.D., is a hematologist/oncologist at City of Hope specializing in stem cell transplantation with an emphasis on the use of umbilical cord blood transplants to treat a growing number of blood cancers.
A bone marrow transplant is a treatment option for some people who have life-threatening blood or immune system diseases, such as leukaemia, multiple myeloma and lymphoma. The procedure replaces blood stem cells in people whose bone marrow has been destroyed by large doses of chemotherapy or radiotherapy.. A bone marrow transplant is a generic term that covers all types of transplants that use stem cells: a blood stem cell transplant, an umbilical cord blood transplant and a bone marrow transplant.. There are different types of bone marrow transplants:. ...
Umbilical cord blood is taken from a new-borns umbilical cord and placenta immediately following birth - a painless, risk-free procedure. Cord blood contains a high concentration of stem cells, and recent studies have shown it provides unique advantages over traditional bone-marrow transplantation. The most significant advantage is that the donor cord blood stem cells do not have to match 100% to the recipients tissue, making finding a suitable match easier.. Cord blood can be used for the baby, the brothers and sisters and the mom and dad with a suitably matching tissue type, and in these instances cord blood stem cell transplants can in fact prove life-saving.. Much like cord blood, umbilical cord tissue can also be collected and stored in a stem cell bank. Cord tissue Mesenchymal stem cells (MSCs) are younger and considered a superior resource when compared to bone marrow MSCs as they are younger and subsequently, they have greater differentiation potential and faster rates of ...
One of our goals is to regularly provide expert public the latest information in the field of the use of stem cells from umbilical cord blood for treatment and research. We would also like to provide an newest information from Slovakia directly related to the area of our cooperation.. Stem Cell Therapy (VIDEO) by Professor Colin McGuckin PhD.. Interview with the renowned British scientists Dr. Peter Hollands, PhD. about stem cells (VIDEO). Private Cord Blood Banking: Current Use and Clinical Future by Dr. Peter Hollands, PhD. & Profesor Catherina McCauley. Umbilical Cord Blood Stem Cells for Regenerative Medicine by Professor Colin McGuckin, PhD.. Family-directed umbilical cord blood banking by Eliane Gluckman, Annalisa Ruggeri, Vanderson Rocha, Etienne Baudoux, Michael Boo, Joanne Kurtzberg, Kathy Welte, Cristina Navarrete, and Suzanna M. van Walraven. Hematopoietic reconstitution in a pacient with Fanconi´s anemia by means of umbilical cord blood from an HLA-identical sibling by Eliane ...
Background: Cell therapy is a potential therapeutic approach for neurodegenerative disorders. Human umbilical cord bloodderived mesenchymal stem cells (hUCB-MSCs) are an appropriate source of stem cells for use in various cell-based therapies. Objectives: In this study, we examined a real-time PCR approach for neural differentiation of hUCB-MSCs in vitro. Materials and Methods: MSCs were cultured in DMEM medium supplemented with 10% FBS in a humidified incubator equilibration at 5% CO2 and 37°C. For the neural differentiation of MSCs, the DMEM was removed and replaced with pre-induction media (retinoic acid [RA], basic fibroblast growth factor [bFGF], and epidermal growth factor [EGF]) and basal medium for two days. They were then cultured in nerve growth factor (NGF), 3-isobutyl-1-methylxanthine (IBMX), ascorbic acid (AA), and basal medium for six days. We also monitored the expression of markers for neural differentiation with real-time PCR. Results: The results of real-time PCR showed that the
The latest market report published by Credence Research, Inc. "Global Umbilical Cord Blood Banking Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025," the umbilical cord blood banking market was valued at USD 2,875.2 Mn in 2016, and is expected to reach USD 7,623.3 Mn by 2025, expanding at a CAGR of 11.3% from 2017 to 2025.. Browse the full report Umbilical Cord Blood Banking Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025 report at http://www.credenceresearch.com/report/umbilical-cord-blood-banking-market. Market Insights. Recently, there has been several changes in the cord blood industry with a few key trends such as diversification of storage services, partnering with prenatal or neonatal or maternal health services, industry consolidation through acquisitions, and focus on cord blood cell expansion. The several diversified services of cord blood banks comprises storage of umbilical cord tissue (Whartons Jelly), ...
Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine ed. by Ana Colette Mauricio ITexLi | 2017 | ISBN: 9535128663 9535128655 9789535128656 9789535128663 | 247 pages | PDF | 34 MB This volume is dedicated to Umbilical cord blood (UCB) and, more recently, umbilical cord tissue (UCT) have been stored cryopreserved in private and public cord blood and tissue banks worldwide, since the umbilical cord blood was used for the first time in a child with Fanconi anemia with his HLA-identical sibling, following strict guidelines that imply high-quality standards and total rastreability of these units.
The National Marrow Donor Program (NMDP) is a nonprofit organization founded in 1986 and based in Minneapolis, Minnesota that operates the Be The Match Registry of volunteer hematopoietic cell donors and umbilical cord blood units in the United States. The Be The Match Registry is the worlds largest hematopoietic cell registry, listing nearly 16 million individuals and nearly 238,000 cord blood units. Hematopoietic cells from NMDP donors or cord blood units are used to transplant patients with a variety of blood, bone marrow or immune system disorders. As of September 2016, the NMDP had facilitated more than 80,000 transplants worldwide. The NMDP coordinates the collection of hematopoietic ("blood-forming") cells that are used to perform what used to be called bone marrow transplants, but are now more properly called hematopoietic cell transplants. Patients needing a hematopoietic cell transplant but who lack a suitably matched donor in their family can search the Be The Match registry for a ...
Myelokathexis is a congenital disorder of the white blood cells that causes severe, chronic leukopenia (a reduction of circulating white blood cells) and neutropenia (a reduction of neutrophil granulocytes). The disorder is believed to be inherited in an autosomal dominant manner. Myelokathexis refers to retention (kathexis) of neutrophils in the bone marrow (myelo). The disorder shows prominent neutrophil morphologic abnormalities. Myelokathexis is amongst the diseases treated with bone marrow transplantation and cord blood stem cells.[citation needed] WHIM syndrome is a very rare variant of severe congenital neutropenia that presents with warts, hypogammaglobunemia, infections, and myelokathexis. A gain in function mutation resulting in a truncated form of CXCR4 is believe to be its cause. WHIM syndrome Aprikyan AA, Liles WC, Park JR, Jonas M, Chi EY, Dale DC (Jan 2000). "Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression ...
PubMed journal article [AN EXPERIMENTAL STUDY ON REPAIR OF SCIATIC NERVE INJURY BY Schwann-LIKE CELLS DERIVED FROM UMBILICAL CORD BLOOD MESENCHYMAL STEM CELLS were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
TY - JOUR. T1 - Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/- umbilical cord blood. AU - Della Chiesa, Mariella. AU - Falco, Michela. AU - Bertaina, Alice. AU - Muccio, Letizia. AU - Alicata, Claudia. AU - Frassoni, Francesco. AU - Locatelli, Franco. AU - Moretta, Lorenzo. AU - Moretta, Alessandro. PY - 2014/2/15. Y1 - 2014/2/15. N2 - NK cells are the first lymphoid population recovering after allogeneic hematopoietic stem cell transplantation and play a crucial role in early immunity after the graft. Recently, it has been shown that humanCMV (HCMV) infection/reactivation can deeply influence NK cell reconstitution after umbilical cord blood transplantation by accelerating the differentiation of mature NKG2A-killer Ig-like receptor (KIR)+ NK cells characterized by the expression of the NKG2C-activating receptor. In view of the hypothesis that NKG2C could be directly involved in NK cell ...

Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic...Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic...

Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic ... Cord Blood Stem Cell Transplantation * Haplotypes * Hematopoietic Stem Cell Transplantation * Histocompatibility Testing ... umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell ...
more infohttps://scholars.duke.edu/display/pub1351433

Umbilical cord-derived mesenchymal stem cells: strategies, challenges, and potential for cutaneous regenerationUmbilical cord-derived mesenchymal stem cells: strategies, challenges, and potential for cutaneous regeneration

Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22(4): 625-634 doi ... Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat ... Stem cell characteristics of amniotic epithelial cells. Stem Cells 2005; 23(10): 1549-1559 doi: 10.1634/stemcells.2004-0357 ... Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24(5 ...
more infohttp://journal.hep.com.cn/fmd/EN/10.1007/s11684-012-0175-9

Global Umbilical Cord Blood Banking Market Is Expected To Reach USD 7,623.3 Mn By 2025 - Credence Research | The Alpha Reporter...Global Umbilical Cord Blood Banking Market Is Expected To Reach USD 7,623.3 Mn By 2025 - Credence Research | The Alpha Reporter...

Rise in hematopoietic stem cell transplantation rates fuelling the demand for umbilical cord blood banking ... and focus on cord blood cell expansion. The several diversified services of cord blood banks comprises storage of umbilical ... China Cord Blood Corporation, Cord Blood America, Inc., Cryo-Cell International, Inc., Cryo-Save AG, Cordlife Group Ltd., Vita ... As umbilical cord blood is one of the rich source of primitive hematopoietic stem cells that are known for its strong ...
more infohttp://www.thealphareporter.com/story/110286/global-umbilical-cord-blood-banking-market-is-expected-to-reach-usd-76233-mn-by-2025-credence-research.html

Global Umbilical Cord Blood Banking Market Is Expected To Reach USD 7,623.3 Mn By 2025 - Credence Research | The Crimson Report...Global Umbilical Cord Blood Banking Market Is Expected To Reach USD 7,623.3 Mn By 2025 - Credence Research | The Crimson Report...

Rise in hematopoietic stem cell transplantation rates fuelling the demand for umbilical cord blood banking ... and focus on cord blood cell expansion. The several diversified services of cord blood banks comprises storage of umbilical ... China Cord Blood Corporation, Cord Blood America, Inc., Cryo-Cell International, Inc., Cryo-Save AG, Cordlife Group Ltd., Vita ... As umbilical cord blood is one of the rich source of primitive hematopoietic stem cells that are known for its strong ...
more infohttp://www.thecrimsonreport.com/story/134802/global-umbilical-cord-blood-banking-market-is-expected-to-reach-usd-76233-mn-by-2025-credence-research.html

Clinical Trial | Unrelated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerClinical Trial | Unrelated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Procedure: allogeneic hematopoietic stem cell transplantation. Procedure: umbilical cord blood transplantation. Radiation: ... are infused into the patient they may help the patients bone marrow make stem cells, red blood cells, white blood cells, and ... When the healthy stem cells from an unrelated donor, that do not exactly match the patients blood, ... Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-intensity ...
more infohttp://comparetrials.com/compare-clinical-trials/unrelated-donor-umbilical-cord-blood-transplant-in-treating-patients-with-hematologic-cancer-3

Cord blood hematopoietic stem cell transplantation | StemBookCord blood hematopoietic stem cell transplantation | StemBook

Broxmeyer, H.E. (2010a). Will iPS Cells Enhance Therapeutic Applicability of Cord Blood Cells and Banking?. Cell Stem Cell 6, ... 2009). Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 5, 353-357. ... 2009). Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 5, 434-441. Abstract Article ... Cord blood hematopoietic stem cell transplantation (May 26, 2010), StemBook, ed. The Stem Cell Research Community, StemBook, ...
more infohttps://www.stembook.org/node/693

Study demonstrates safety of cord blood stem cell transplantation protocol to treat neurological conditionsStudy demonstrates safety of cord blood stem cell transplantation protocol to treat neurological conditions

... in Shenzhen using Beikes proprietary cord blood stem cell transplantation protocol. ... Chinas leading stem cell research and regenerative medicine company, and Medistem, Inc.,reported positive safety data in 114 ... Study demonstrates safety of cord blood stem cell transplantation protocol to treat neurological conditions. *Download PDF Copy ... in Shenzhen using Beikes proprietary cord blood stem cell transplantation protocol.. The peer-reviewed paper is available at ...
more infohttps://www.news-medical.net/news/20100903/Study-demonstrates-safety-of-cord-blood-stem-cell-transplantation-protocol-to-treat-neurological-conditions.aspx

Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer - Full Text View -...Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer - Full Text View -...

Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer. The safety and scientific ... The purpose of this study is to examine the immune system response to cord blood stem cell transplantation in adults with ... The purpose of this study is to evaluate the effectiveness of umbilical cord blood stem cell transplantation in adults with ... Umbilical cord blood is an important source of stem cells and can be used to treat blood and immune system disorders and ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT00312429

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases |...Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases |...

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases ... Childhood Langerhans Cell Histiocytosis , Leukemia , Sarcoma , Lymphoma , Protocol Specific , ... Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Brief ... Cord blood transplant: All patients undergo umbilical cord blood transplantation on day 0. - Graft-versus-host disease ...
more infohttp://www.centerwatch.com/clinical-trials/listings/23787/childhood-langerhans-cell-histiocytosis-umbilical-cord-blood-stem/?radius=50

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases - Full...Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases - Full...

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases. The ... Cord blood transplant: All patients undergo umbilical cord blood transplantation on day 0. ... RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or ... Impact of the use of umbilical cord blood as a source of hematopoietic stem cells. *Comparison of the incidence of graft-vs- ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00084695?cond=%22Langerhans+cell+histiocytosis%22&rank=11

Prolonged Survival of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with...Prolonged Survival of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with...

... of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with Umbilical Cord Blood ... Although hematopoietic stem cell transplantation (HSCT) has been considered to be the only way for potential cure of relapsed ... She was treated with a toxicity reduced conditioning regimen and received direct intrabone cord blood transplantation (CBT) ... using a single unit of 5/6 HLA-matched cord blood as a graft source. Graft-versus-host disease prophylaxis was performed with a ...
more infohttps://www.hindawi.com/journals/crihem/2014/918708/abs/

Prolonged Survival of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with...Prolonged Survival of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with...

... of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with Umbilical Cord Blood ... Although hematopoietic stem cell transplantation (HSCT) has been considered to be the only way for potential cure of relapsed ... F. Frassoni, F. Gualandi, M. Podestà et al., "Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a ... M. J. Laughlin, M. Eapen, P. Rubinstein et al., "Outcomes after transplantation of cord blood or bone marrow from unrelated ...
more infohttps://www.hindawi.com/journals/crihem/2014/918708/

Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with...Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with...

Cord blood transplantation (UCBT) and non-T-cell-depleted stem cell transplantation from haploidentical donors (HAPLO) are both ... Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with ... Medical Park, Stem Cell Transplant Unit, Antalya, Turkey.. 12. Erasmus MC Cancer Institute, University Medical Centre, ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/31150016

About Cord Blood Stem Cell TransplantationAbout Cord Blood Stem Cell Transplantation

There are several people whose stem cells have found to be extirpated or weakened due to some genetic or chronic disease. Such ... Cord Blood Stem Cells. These days, umbilical cord blood has been considered to be an easy and healthy stem cell source. Along ... white blood cells and red blood cells. Different stem cell sources are found today. The primary source pertaining to stem cells ... cord blood is found to be a good stem cell source which could be stored, processed and retrieved. Cord blood can be obtained ...
more infohttp://www.nachoserapio.com/about-cord-blood-stem-cell-transplantation/

New technique expands number of functional cord blood stem cells for transplantationNew technique expands number of functional cord blood stem cells for transplantation

Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood (CB) stems ... cells to generate in greater numbers making them more useful in adult transplantation. ... and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. ... Cord blood stem cells have always posed limitations for adult patients because of the small number of stem cells present in a ...
more infohttps://www.news-medical.net/news/20140508/New-technique-expands-number-of-functional-cord-blood-stem-cells-for-transplantation.aspx

Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. - Semantic...Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. - Semantic...

These results suggest that ALC recovery is an important prognostic indicator for patients treated with cord blood and T cell- ... We retrospectively analyzed 65 consecutive patients treated at our institution with cord blood (n = 37) and haploidentical (n ... 28) transplantation with myeloablative fludarabine, melphalan, and thiotepa conditioning. Patients with lymphocyte recovery at ... Alternative donor stem cell transplantation from cord blood or haploidentical peripheral blood donors is increasingly being ...
more infohttps://www.semanticscholar.org/paper/Lymphocyte-recovery-predicts-outcomes-in-cord-blood-Ciurea-Mulanovich/b07383e95ef4472e18784e49cefc3d55846c964a

Infectious Complications in Patients Undergoing Reduced Intensity Stem Cell Transplantation (RIST) from Unrelated Umbilical...Infectious Complications in Patients Undergoing Reduced Intensity Stem Cell Transplantation (RIST) from Unrelated Umbilical...

BACKGROUND: Reduced intensity stem cell cell transplantation (RIST) from unrelated umbilical cord blood (RI-UCBT) is a novel ... Infectious Complications in Patients Undergoing Reduced Intensity Stem Cell Transplantation (RIST) from Unrelated Umbilical ... Department of Hematology, Toranomon Hospital, Tokyo, Japan; Hematopoietic Stem Cell Transplantation Unit, National Cancer ... Cord Blood (RI-UCBT). Session Type: Publication Only Koichiro Yuji, Shigesaburo Miyakoshi, Daisuke Kato, Eiji Kusumi, Masahiro ...
more infohttps://www.aspergillus.org.uk/content/infectious-complications-patients-undergoing-reduced-intensity-stem-cell-transplantation

Reduced intensity conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from...Reduced intensity conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from...

... conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from unrelated cord blood ... conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from unrelated cord blood ... conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from unrelated cord blood ... conditioning and allogeneic stem cell transplantation in children and adolescents with malignancies from unrelated cord blood ...
more infohttp://cancerres.aacrjournals.org/content/64/7_Supplement/718.1

Functional improvement of patients with progressive muscular dystrophy by bone marrow and umbilical cord blood mesenchymal stem...Functional improvement of patients with progressive muscular dystrophy by bone marrow and umbilical cord blood mesenchymal stem...

2) CB-MSC: 80 - 160 ml umbilical cord blood was harvested and processed likewise as above. (3) Stem cell transplantation: Both ... Eighty-two patients underwent the double transplantations of bone mesenchymal stem cell (BMSC) and human umbilical cord blood ... and umbilical cord mesenchymal stem cells (UMSC) in the treatment of progressive muscular dystrophy (PMD). METHODS A total of ... CONCLUSION The double transplantation of BMSC and CB-MSC is convenient, safe and effective in the treatment of progressive ...
more infohttps://www.semanticscholar.org/paper/Functional-improvement-of-patients-with-progressi-Yang-Xu/f04d05f4ce41af72de711128c6766df95d02716c

Epigenetically Reprogrammed Cells Generate Functional Cord Blood Stem Cells for Transplantation - The ASCO PostEpigenetically Reprogrammed Cells Generate Functional Cord Blood Stem Cells for Transplantation - The ASCO Post

The use of cord blood cells as hematopoietic stem cell grafts for patients with blood cancers receiving an allogeneic stem cell ... Epigenetically Reprogrammed Cells Generate Functional Cord Blood Stem Cells for Transplantation. By Jo Cavallo. Posted: 5/13/ ... of functional cord blood stem cells can be generated by epigenetically reprogramming dividing cord blood CD34-positive cells ... cord blood cells as hematopoietic stem cell grafts for patients with hematologic malignancies receiving an allogeneic stem cell ...
more infohttps://www.ascopost.com/News/16216

Umbilical cord blood hematopoietic stem cell transplantation, an alter by Kyaw Thu Minn and Mortada Salman Najem"Umbilical cord blood hematopoietic stem cell transplantation, an alter" by Kyaw Thu Minn and Mortada Salman Najem

However, double cord blood transplantation has been faced with the challenge of single unit dominance in most studies. Ex vivo ... is an alternative hematopoietic stem cell (HSC) source that can ameliorate several diseases through transplantation. The ... purpose of this project is to analyze clinical studies comparing HSCs from a single cord blood unit (CBU) to HSCs from bone ... It was found that UCB transplantation in adults is a viable method when a matched bone marrow transplant cannot be identified. ...
more infohttps://digitalcommons.wpi.edu/iqp-all/3202/

Effect of human umbilical cord blood mesenchymal stem cell transplantation on neuronal metabolites in ischemic rabbits | BMC...Effect of human umbilical cord blood mesenchymal stem cell transplantation on neuronal metabolites in ischemic rabbits | BMC...

... we transplanted human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) into cerebral ischemic rabbits and examined the ... positive cells. We also evaluated complete blood cell counts(CBCs) and serum biochemical parameters. NSSs in the hUCB-MSC group ... providing additional evidence for neuroprotection by stem cells. No significant changes were observed in CBCs or serum ... The effects of hUCB-MSC transplantation were assessed by proton magnetic resonance spectroscopy (1H-MRS), neurological severity ...
more infohttps://bmcneurosci.biomedcentral.com/articles/10.1186/1471-2202-15-41

Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation<...Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation<...

Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation. / ... Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation. ... Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation. ... Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation, ...
more infohttps://pure.fujita-hu.ac.jp/en/publications/generation-of-hla-a2-subtype-specific-cytotoxic-t-lymphocytes-fro

Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development | FierceBiotechStem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development | FierceBiotech

Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking ... Tissue Banking and Transplantation Industry: Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug ... Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development ... Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug ...
more infohttps://www.fiercebiotech.com/biotech/stem-cells-worldwide-markets-for-transplantation-cord-blood-banking-and-drug-development

Umbilical cord blood banking in the worldwide hematopoietic stem cell transplantation system: perspectives for Ukraine |...Umbilical cord blood banking in the worldwide hematopoietic stem cell transplantation system: perspectives for Ukraine |...

Significant progress in the promotion of procedural technologies associated with the transplantation of hematopoietic stem ... Blood 2008; 112: 4318-27.. *41. Danby R, Rocha V. Clinical use of umbilical cord blood cells. In: Cord blood stem cells ... allogeneic transplantation, cord blood bank, donor registries, hematopoietic stem cell, umbilical cord blood ... Cord Blood Stem Cells Medicine. Academic Press. Elsevier Inc, 2015: xvii.. *27. Katz G. Cord blood banking in France: ...
more infohttp://exp-oncology.com.ua/article/10105/umbilical-cord-blood-banking-in-the-worldwide-hematopoietic-stem-cell-transplantation-system-perspectives-for-ukraine?pdf
  • Alloantigen reactive cytotoxic T lymphocytes (CTL) were generated from cord blood (CB) lymphocytes used for cord blood stem cell transplantation (CBSCT). (fujita-hu.ac.jp)
  • They found that after an initial 16-hour cytokine priming, the cells treated with the most active HDAC inhibitor, valproic acid, increased the number of multipotent (CD34-positive and CD90-positive) cells that were generated. (ascopost.com)
  • The second flawed assumption is that the stem cells in the UCB unit will exhibit the same quality and potency when they are thawed and prepared for a patient, as they did when the unit was collected and tested prior to cryopreservation. (parentsguidecordblood.org)
  • HemoGenix assays can measure stem cell quality before cryopreservation ( STEMpredict ) and potency after thawing ( HALO-96 PQR ) . (parentsguidecordblood.org)
  • Cord blood collection is typically depleted of red blood cells before cryopreservation to ensure high rates of stem cell recovery. (wikipedia.org)
  • Therefore, elucidation of potential mechanisms of action is vital to further develop stem cell therapies for translation to the bedside. (biomedcentral.com)
  • There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. (fiercebiotech.com)
  • stem cells may also eventually permit drug developers to test emerging therapies on diseased cells. (fiercebiotech.com)
  • The purpose of this study is to examine the immune system response to cord blood stem cell transplantation in adults with advanced blood disorders or cancer. (clinicaltrials.gov)
  • Cord blood has been used successfully in pediatric patients but its benefit in adults remains untested. (clinicaltrials.gov)
  • Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. (springer.com)
  • Candidates for HSCTs include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia with defective stem cells, and also children or adults with aplastic anemia who have lost their stem cells after birth. (wikipedia.org)
  • Transplanted hUCB-MSCs might ameliorate ischemic damage by influencing neuronal metabolites in the infarct area, providing additional evidence for neuroprotection by stem cells. (biomedcentral.com)
  • Thus, means to enhance numbers and/or potency of collected cells and their engrafting capability through ex-vivo and/or in-vivo maneuvers would likely enhance the efficacy and applicability of CB transplantation. (stembook.org)
  • Dr. Wanzhang Yang, who led the study at Nanshan Affiliated Hospital of Guangdong Medical College commented, 'This important study, which is the largest of its kind, demonstrates the safety and efficacy of using cord-blood-derived stem cells to treat a variety of neurological conditions. (news-medical.net)
  • Researchers used a technique called epigenetic reprogramming which reshaped cell DNA by treating cells with a combination of histone deacetylase inhibitors (HDACI) and valproic acid. (news-medical.net)
  • Compared with the cord blood CD34-positive cells, the valproic acid-treated CD34-positive cells produced a greater number of severe combined immunodeficiency-repopulating cells and established multilineage hematopoiesis in primary and secondary immune-deficient recipient mice. (ascopost.com)